April 26, 2022
Chemically Harnessing Novel E3 Ligases Biology for Next-generation TPD Therapeutics
2nd Annual Ligase Targeting Drug Development Summit
Read More
April 7, 2022
KT-253, a highly potent and selective heterobifunctional MDM2 degrader for the treatment of wildtype p53 tumors with superior potency and differentiated biological activity compared to small molecule inhibitors (SMI)
American Association for Cancer Research Annual Meeting
Liquid Tumors
Solid Tumors
Read More
December 13, 2021
Selective STAT3 Degraders Dissect Peripheral T-Cell Lymphomas Vulnerabilities Empowering Personalized Regimens
The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
December 13, 2021
A First-in-Class STAT3 Degrader KT-333 in Development for Treatment of Hematologic Cancers
The 63rd Annual ASH Meeting and Exposition
Liquid Tumors
Read More
November 12, 2021
Targeted STAT3 Degradation Leads to Remodeling of an Immunosuppressive Tumor Microenvironment and Subsequent Sensitization to Immune Checkpoint Inhibition
SITC 2021
Liquid Tumors
Solid Tumors
Read More
October 28, 2021
Considerations for E3 Ligase Pairing and Screening of Immune-Inflammation Targets
4th Annual TPD Summit
Read More
October 27, 2021
Understanding PK/PD for Development of STAT3 Degraders in Oncology Indications
4th Annual TPD Summit
Liquid Tumors
Solid Tumors
Read More
October 27, 2021
Safety, PK and PD from Single Ascending Does Portion of KT-474 Phase 1 Trial in Healthy Volunteers
4th Annual TPD Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
October 26, 2021
TPD Workshop: De-risking Clinical Development of a Novel Protein Degrader
4th Annual TPD Summit
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More
September 21, 2021
Identification of Highly Potent and Selective Interleukin-1 Receptor Associates Kinase 4 (IRAK4) Degrader for the Treatment of Autoimmune Disease
European Protein Degradation Congress
Atopic Dermatitis (AD)
Hidradenitis Suppurativa (HS)
Read More